JP2019525923A5 - - Google Patents

Download PDF

Info

Publication number
JP2019525923A5
JP2019525923A5 JP2019503485A JP2019503485A JP2019525923A5 JP 2019525923 A5 JP2019525923 A5 JP 2019525923A5 JP 2019503485 A JP2019503485 A JP 2019503485A JP 2019503485 A JP2019503485 A JP 2019503485A JP 2019525923 A5 JP2019525923 A5 JP 2019525923A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
delivered
eye
des
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019503485A
Other languages
English (en)
Japanese (ja)
Other versions
JP6889771B2 (ja
JP2019525923A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/042382 external-priority patent/WO2018017479A1/en
Publication of JP2019525923A publication Critical patent/JP2019525923A/ja
Publication of JP2019525923A5 publication Critical patent/JP2019525923A5/ja
Application granted granted Critical
Publication of JP6889771B2 publication Critical patent/JP6889771B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019503485A 2016-07-18 2017-07-17 ドライアイ症候群を治療する方法 Active JP6889771B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662363565P 2016-07-18 2016-07-18
US201662363592P 2016-07-18 2016-07-18
US62/363,565 2016-07-18
US62/363,592 2016-07-18
US201662436727P 2016-12-20 2016-12-20
US62/436,727 2016-12-20
PCT/US2017/042382 WO2018017479A1 (en) 2016-07-18 2017-07-17 Methods of treating dry eye syndrome

Publications (3)

Publication Number Publication Date
JP2019525923A JP2019525923A (ja) 2019-09-12
JP2019525923A5 true JP2019525923A5 (https=) 2019-10-24
JP6889771B2 JP6889771B2 (ja) 2021-06-18

Family

ID=60992530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503485A Active JP6889771B2 (ja) 2016-07-18 2017-07-17 ドライアイ症候群を治療する方法

Country Status (8)

Country Link
US (2) US10960051B2 (https=)
EP (1) EP3484497A4 (https=)
JP (1) JP6889771B2 (https=)
KR (1) KR102488796B1 (https=)
CN (1) CN109789182A (https=)
AU (1) AU2017300268B2 (https=)
CA (1) CA3031069A1 (https=)
WO (1) WO2018017479A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7570228B2 (ja) * 2020-12-25 2024-10-21 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置
JP2022102757A (ja) * 2020-12-25 2022-07-07 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置
JP7570229B2 (ja) * 2020-12-25 2024-10-21 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503527A (ja) 1990-02-22 1993-06-10 マクノート・ピーティーワイ・リミテッド 人工涙液
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
AU2002255736B2 (en) 2001-03-15 2006-08-31 Regenerx, Biopharmaceuticals, Inc. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (Tbeta4), analogues, isoforms and other derivatives
WO2003020215A2 (en) * 2001-08-29 2003-03-13 Regenerx Biopharmaceuticals, Inc. Methods of treating mycocardial event related coditions with thymosin beta 4
ES2619426T3 (es) * 2005-01-13 2017-06-26 Regenerx Biopharmaceuticals, Inc. Timosina beta 4 para el tratamiento de la esclerosis múltiple
CN101198344A (zh) * 2005-06-17 2008-06-11 雷金纳克斯生物制药公司 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物
JP2008543877A (ja) * 2005-06-17 2008-12-04 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔ組成物および組織の悪化、傷害または損傷を処置または予防するための方法
CN101152568A (zh) * 2006-09-25 2008-04-02 宝勒日 具有促进血管形成、组织再生及伤口愈合作用的多肽组合制剂
NZ582188A (en) * 2007-07-11 2012-03-30 Pfizer Pharmaceutical compositions and methods of treating dry eye disorders

Similar Documents

Publication Publication Date Title
US11458189B2 (en) Cytoprotective drugs
PE20241305A1 (es) Analogos de amilina
Ji et al. Resveratrol attenuates retinal ganglion cell loss in a mouse model of retinal ischemia reperfusion injury via multiple pathways
TWI670057B (zh) 治療乾眼用滴眼劑
CN104940926B (zh) 重组融合蛋白制剂
Zhang et al. Doxycycline alleviates paraquat-induced acute lung injury by inhibiting neutrophil-derived matrix metalloproteinase 9
Vavrinec et al. Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat
JP2019525923A5 (https=)
IL273531B1 (en) Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
JP2021515758A5 (https=)
WO2016045626A1 (zh) 重组融合蛋白制剂
CN102066402B (zh) 肽衍生物以及含有肽衍生物的用于促进泪液分泌的组合物
JP2015025011A5 (https=)
Fu et al. Overexpression of angiotensin-converting enzyme 2 ameliorates amyloid β-induced inflammatory response in human primary retinal pigment epithelium
Imai et al. Triamcinolone acetonide suppresses inflammation and facilitates vascular barrier function in human retinal microvascular endothelial cells
AU2017261303A1 (en) Ophthalmic compositions
JP2021519773A (ja) 炎症性サイトカインを阻害するための医薬組成物
JP2023099171A (ja) 緑内障を治療するためのＷｎｔ５ａの調節
Zhou et al. The molecular mechanisms of action of PPAR-γ agonists in the treatment of corneal alkali burns
EA201891730A1 (ru) Офтальмологическая композиция для применения при лечении офтальмологических расстройств, связанных с изменениями роговично-конъюнктивальной поверхности
JP2018500546A5 (https=)
CN107320725B (zh) 一种抑制近视的方法及制备药物的应用
MA50991A (fr) Composition ophtalmique topique comprenant de l'acide dobésilique pour le traitement de maladies du segment postérieur de l'oeil
CN109789182A (zh) 治疗干眼综合征的方法
Gu et al. Glucocorticoid-induced leucine zipper overexpression inhibits lipopolysaccharide-induced retinal inflammation in rats